About Us
A Leader in Innate Immunity
At IFM Therapeutics, LLC, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response.
The majority of advances in immunotherapy have focused largely on targeting the adaptive immune system, which historically has been the best-characterized part of the immune system. While many of these approaches can work well, the benefit is seen only in a small number of diseases and over time, patients can lose response to these therapies. However, our understanding of the innate immune system has matured sufficiently, that we can now think about exploiting this biology to advance a new generation of medicines for inflammatory disorders and cancer. IFM Therapeutics, LLC has brought together the key academic thought leaders and advisors in this field, along with an exceptionally talented group of pharmaceutical scientists and executives, to make this goal a reality.
IFM Therapeutics, LLC was formed following the acquisition of IFM Therapeutics by Bristol-Myers Squibb in 2017. IFM Therapeutics, LLC retained its personnel and facilities, as well as its remaining research programs focused on curbing immune responses that lead to inflammatory diseases and fibrosis.
By focusing on innate immunity, IFM Therapeutics, LLC is looking to solve the limitations faced by current immunotherapies by dramatically increasing the number of patients that benefit from treatment and extending the duration of therapeutic response.
Building on
Expertise and Innovation
Our company was founded by an international group of preeminent scientists and physicians who have spent decades unraveling the complexities of innate immunity and the role it plays in health and disease. We have assembled an unparalleled team committed to innovation and scientific rigor to rapidly develop a novel pipeline of drug candidates.
Meet Our Leadership Team
We have assembled a tailor-made team with proven expertise in developing transformative medicines that will further our goal of bringing the most promising immunotherapies to patients with inflammatory diseases and cancer.
Gary D. Glick
H. Martin Seidel
Dennis Dean
William R. Roush
Lina Gugucheva
Ed Olhava
Gary D. Glick
Jean-François Formela
Vincent Miles
John Leonard
Shelley Chu
Michael Gladstone
Matthew Roden
Gary D. Glick
Luigi Franchi
Matthias Geyer
Eicke Latz
Anthony Opipari
Jasmin Kümmerle-Deschner, M.D.
Head, Division of Pediatric Rheumatology and autoinflammation reference center Tübingen, Department of Pediatrics at the University Hospital of Tübingen, Germany
Peter Libby, M.D.
Cardiovascular Specialist, Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School
Giovanni Monteleone, M.D., Ph.D.
Professor of Gastroenterology, Chief of the Gastroenterology and Endoscopic Division, Systems Medicine Department, University of Rome Tor Vergata, Rome, Italy
Markus F. Neurath, M.D.
Chair of Internal Medicine, University of Erlangen-Nürnberg, Germany
D. Brent Polk, M.D.
Professor of Pediatrics and Biochemistry and Molecular Medicine, Keck School of Medicine University of Southern California
David T. Rubin, M.D.
Joseph B. Kirsner Professor of Medicine, Section Chief, Gastroenterology, Hepatology, Nutrition and Co-Director of the Digestive Diseases Center, University of Chicago
Arun J. Sanyal, M.D.
Professor, Department of Internal Medicine and Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University
Scott B. Snapper , M.D., Ph.D.
Director, Inflammatory Bowel Disease Center and Professor of Medicine, Professor of Pediatrics, Harvard Medical School
Michael Heneka, M.D.
Director, Department of Neurodegenerative Diseases and Gerontopsychiatry, University Hospital of Bonn, Germany
Hal Hoffman, M.D.
Professor of Pediatrics and Medicine and Chief of the Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego
Howard Kauffman, M.D., F.A.C.S.
Professor of Surgery and Medicine, Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey
Saurabh Saha, M.D., Ph.D.
Senior Vice President and Global Head of Translational Medicine, Bristol-Myers Squibb
Diane Mathis, PhD (Chair)
Professor of Microbiology and Immunobiology, Harvard Medical School
Member, National Academy of Sciences
Andrea Ablasser, MD
Assistant Professor, École Polytechnique Fédérale de Lausanne (EPFL)
Erick M. Carreira, PhD
Head, Laboratory of Organic Chemistry, ETH Zürich
Douglas T. Fearon, MD FRS FMedSci
Professor, Cold Spring Harbor Laboratory
Walter B. Wriston Professor of Pancreatic Cancer Research, Weill Cornell Medicine
Emeritus Sheila Joan Smith Professor of Immunology, University of Cambridge
Member, National Academy of Sciences
Nir Hacohen, PhD
Director, Center for Cancer Immunology, Massachusetts General Hospital
Harvard Medical School
Broad Institute
William L. Jorgensen, PhD
Sterling Professor of Chemistry, Yale University
Member, National Academy of Sciences
Jonathan C. Kagan, PhD
Associate Professor of Pediatrics, Harvard Medical School
Shwachman Chair in Gastroenterology, Staff Scientist, Boston Children's Hospital
Vito Palombella, PhD
Chief Scientific Officer, Surface Oncology
Alexander Rudensky, PhD
Chairman, Immunology Program, Sloan-Kettering Institute
Investigator, Howard Hughes Medical Institute
Director, Ludwig Center for Cancer Immunotherapy
Tri-Institutional Professor at MSKCC, The Rockefeller University and Cornell University
Member, National Academy of Sciences
Awards and Nominations
At IFM Therapeutics, we're proud of our team's achievements in science and industry.
